# Data Sharing Statement

| Article Info | http://dx.doi.org/10.21037/jtd-20-3520. |
|--------------|----------------------------------------|
| **Item**     | **Question**                           | **Authors’ Response (place “-” if not applicable)** |
| 1            | Would you like to share data collected for your study to others? | Yes |
| 2            | If not, would you like to share the reason for your decision? | - |
| 3            | What data in particular will be shared? | The survival data will be shared. |
| 4            | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Study protocol and statistical analysis plan will also be shared if requested. |
| 5            | When will data availability begin? | From the publication date. |
| 6            | When will data availability end? | Two years within the publication date, since the technique or survival date may be updated over time. |
| 7            | To whom will you share the data? | Medical Oncologists and surgeons of thoracic surgery who are distinguish societies interested in this study. |
| 8            | For what type of analysis or purpose? | For analysis to evaluate the efficacy and safety of ICIs for patients with advanced lung cancer and heavily treated with the EGFR mutation |
| 9            | How or where can the data/documents be obtained? | Emails could be sent to the address below to obtain the shared data:jifeng_feng@163.com |
| 10           | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |